NCT02225002

Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Completed Phase 1 Last updated 24 August 2018

What this trial tests

Phase 1 trial testing CP-870,893 in Advanced Solid Tumors. Completed in 1 February 2006.

Timeline

1 January 2004

Primary endpoint
1 February 2006

1 February 2006

Quick facts

Lead sponsor	Abramson Cancer Center at Penn Medicine
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Start date	1 January 2004
Primary completion	1 February 2006
Estimated completion	1 February 2006
Sites	1 location across United States

Drugs / interventions tested

• CP-870,893

Conditions studied

• Advanced Solid Tumors — all drugs for Advanced Solid Tumors →

Sponsor

Abramson Cancer Center at Penn Medicine — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Number of Adverse Events
  Time frame: 2 years

Sponsor's own description

CD40, a member of the Tumor Necrosis Factor receptor superfamily, is expressed on many tumor types, including melanoma, prostate, colon, breast, renal, pancreatic, and nonsmall cell lung cancers. In preclinical models, activation of CD40 results in increased antigen presentation and induction of apoptosis. CD40 is also expressed on antigen presenting cells (APCs) (B cells, dendritic cells, monocytes) and is a key regulator of both cellular and humoral immune responses. Activation of CD40 by CP-870,893, an agonistic anti-CD40 monoclonal antibody, enhances host immune responses and abrogates the growth of tumors independently of the expression of CD40 on tumor cells. Therefore, it is hypothesized that therapeutic intervention with CP-870,893 may be beneficial to a large number of cancer patients either through an immunomodulatory effect or through a direct effect on CD40-positive tumor cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Immunotherapy in colorectal cancer: rationale, challenges and potential.
   Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, et al · · 2019 · cited 1407× · PMID 30886395 · DOI 10.1038/s41575-019-0126-x
2. Macrophages as tools and targets in cancer therapy.
   Mantovani A, Allavena P, Marchesi F, Garlanda C. · · 2022 · cited 1279× · PMID 35974096 · DOI 10.1038/s41573-022-00520-5
3. Macrophages and therapeutic resistance in cancer.
   Ruffell B, Coussens LM. · · 2015 · cited 1235× · PMID 25858805 · DOI 10.1016/j.ccell.2015.02.015
4. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment.
   Kim SK, Cho SW. · · 2022 · cited 300× · PMID 35685630 · DOI 10.3389/fphar.2022.868695
5. Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses.
   Anfray C, Ummarino A, Andón FT, Allavena P. · · 2019 · cited 222× · PMID 31878087 · DOI 10.3390/cells9010046
6. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.
   Dieci MV, Miglietta F, Guarneri V. · · 2021 · cited 168× · PMID 33498711 · DOI 10.3390/cells10020223
7. Exploiting innate immunity for cancer immunotherapy.
   Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
8. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
   Beatty GL, Li Y, Long KB. · · 2017 · cited 120× · PMID 27927088 · DOI 10.1080/14737140.2017.1270208